HK Stock Market Move | WYNN MACAU(01128) drops over 4% after performance results. Property EBITDA in the fourth quarter of 25 years dropped 7% year-on-year, falling 10% below market expectations.

11:04 13/02/2026

Wynn Macau (01128) fell by over 4%, as of the time of writing, dropping by 4.58% to HK$5.83, with a turnover of HK$40.53 million.

WYNN MACAU (01128) fell more than 4% after the results, dropping 4.58% to HKD 5.83 as of press time with a trading volume of HKD 40,534,800. On the news front, on February 13th, WYNN MACAU released the fourth quarter and annual results of its controlling shareholder WYNN RESORTS, LIMITED for the period ending December 31, 2025. In the fourth quarter of 2025, adjusted EBITDAR for Las Vegas operations, Wynn Palace, Encore Boston Harbor, and Wynn Macau decreased by USD 26.6 million, USD 21.1 million, USD 1.8 million, and USD 0.7 million respectively compared to the fourth quarter of 2024. According to a research report released by UBS, WYNN MACAU's property EBITDA for the fourth quarter of 2025 decreased annually by 7% to HKD 2.113 billion, meeting expectations but falling 10% below market expectations due to declines in VIP and mass market win rates. The property EBITDA profit margin contracted by 3.6 percentage points to 28% year-on-year, also in line with expectations. Additionally, the company revised its 2026 capital expenditure guidance from USD 450 million-500 million to USD 400 million-450 million.

PCPD(00432) plans to sell Midtown Niseko, a Japanese eco-hotel, for 80 million US dollars.

Shenzhen Woer Heat-shrinkable Material (09981) has been included in the list of securities eligible for Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.

SSY GROUP(02005): Propranolol hydrochloride has been approved by the Chinese drug regulatory authority as a raw material for use in marketed formulations.

PCPD(00432) plans to sell Midtown Niseko, a Japanese eco-hotel, for 80 million US dollars.

Shenzhen Woer Heat-shrinkable Material (09981) has been included in the list of securities eligible for Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.

SSY GROUP(02005): Propranolol hydrochloride has been approved by the Chinese drug regulatory authority as a raw material for use in marketed formulations.